Welcome to our dedicated page for MBX Biosciences SEC filings (Ticker: MBX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The MBX Biosciences, Inc. (Nasdaq: MBX) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. As a clinical-stage biopharmaceutical company and emerging growth company, MBX uses filings such as Forms S-1, 10-K, 10-Q, and 8-K to describe its Precision Endocrine Peptide™ (PEP™) platform, clinical programs, risk factors, and capital-raising activities.
In its S-1 registration statement, MBX outlines its focus on novel precision peptide therapies for endocrine and metabolic disorders and details key product candidates, including canvuparatide (MBX 2109) for chronic hypoparathyroidism, imapextide (MBX 1416) for post-bariatric hypoglycemia, and MBX 4291 for obesity. Subsequent 8-K filings report material events such as topline results from the Phase 2 Avail™ trial of canvuparatide, initiation of the Phase 1 trial of MBX 4291, public equity offerings, and changes in board and committee roles.
Through this page, users can review MBX’s periodic financial reports, which discuss research and development spending, cash and marketable securities, and expectations about funding operations, as well as prospectus materials that describe intended uses of offering proceeds. Form 8-K filings also summarize key clinical data, trial designs, and future development plans for the company’s programs.
Stock Titan enhances these filings with AI-powered summaries that highlight the main points of lengthy documents, helping readers quickly understand topics such as clinical results, financing terms, and governance updates. Real-time updates from EDGAR, along with structured access to material event reports and registration statements, make this page a central resource for analyzing MBX’s regulatory and financial disclosures.
Deep Track Capital, Deep Track Biotechnology Master Fund and David Kroin report shared beneficial ownership of 2,188,592 common shares of MBX Biosciences, representing 6.55% of the outstanding common stock. The filing shows the reporting persons hold shared voting and shared dispositive power over these shares, and the percent is calculated using 33,424,371 shares outstanding per the issuer's disclosure. The statement is a joint filing under Schedule 13G, identifying the reporting persons and their filing classifications (Deep Track Capital: IA, OO; Deep Track Biotechnology Master Fund: CO; David Kroin: HC, IN), and certifies the holdings were not acquired to change or influence control.
Wellington Management affiliates report beneficial ownership of 2,266,628 shares of MBX Biosciences common stock, shown on the cover pages as 6.8% of the class and noted elsewhere as 6.78%. Four Wellington entities are listed as reporting persons and the schedules show no sole voting or dispositive power, with voting and disposition attributed on a shared basis.
The filing includes an Item 10 certification that the securities are held in the ordinary course of business and were not acquired to change or influence control. The statement indicates these positions are held of record by clients of Wellington investment advisers and names two funds with specified interests.
MBX Biosciences 10-Q (Q2 2025) — MBX reported cash, cash equivalents and marketable securities of $224.9 million and an accumulated deficit of $180.8 million as of June 30, 2025. Net loss was $43.3 million for the six months ended June 30, 2025; R&D expense was $40.13 million for the same period.
Development updates: enrollment for the Phase 2 canvuparatide trial is complete with topline data expected in Q3 2025; imapextide reported positive Phase 1 SAD/MAD results and a Phase 2a is anticipated to start in Q3 2025; MBX 4291 IND was submitted June 16, 2025 and cleared in July 2025 to proceed to Phase 1 in Q3 2025. Management expects liquidity to fund operations into mid-2027.